F-star Therapeutics names James Sandy as CDO

2 March 2022

UK and USA-based clinical-stage biopharmaceutical company F-star Therapeutics (Nasdaq: FSTX) has appointed James Sandy as chief development officer (CDO), effective March 1. Mr Sandy will lead the clinical development and advancement of F-star’s pipeline.

“We are delighted to welcome James to F-star,” said Eliot Forster, chief executive of F-star Therapeutics, adding: “James brings an unparalleled depth of experience in drug development in oncology and a strong track record of enhancing and accelerating clinical operational capabilities. I look forward to working with James as a member of the executive leadership team, as we advance our clinical pipeline and prepare for multiple data readouts this year.”

Mr Sandy brings over 35 years of experience in the pharmaceutical and biotechnology industries across all phases of drug development. Before joining F-star Therapeutics Mr Sandy served as CDO at Ellipses Pharma, Immunocore, and Creabilis Pharmaceuticals. Earlier in his career, Mr Sandy held senior positions with Pfizer.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK